UTI Mid Cap Fund · Regular · Growth
NAV
₹310.0953
as of 15 Jul 2026
Expense Ratio
1.77%
AUM
₹11,473 Cr
Lumpsum returns (CAGR)
- 1Y
- +1.43%
- 3Y
- +13.13%
- 5Y
- +12.58%
- Since Inception
- +16.60%
SIP returns (XIRR)
- 1Y
- +6.87%
- 3Y
- +7.74%
- 5Y
- +11.75%
- Since Inception
- +15.95%
Returns calculated from 22 August 2014 onwards due to a structural change in the scheme on that date. Earlier NAV history is preserved but excluded from multi-year return calculations. Periods spanning this date show —.
What history actually did — last 10 years (Jul 2016 – Jul 2026)
A ₹5,000 monthly SIP for the last 10 years (Jul 2016 – Jul 2026)
Real NAV backtest
A ₹5,000 monthly SIP would be worth ₹12,97,469 today — ₹6,00,000 invested, 14.9% XIRR.
₹6,00,000
Invested
₹12,97,469
Value today
14.9%
XIRR (p.a.)
A ₹1,00,000 lumpsum, the last 10 years (Jul 2016 – Jul 2026)
Real NAV backtest
₹1,00,000 invested 10 years ago would be ₹3,62,772 today (13.8% CAGR).
A regular withdrawal plan (SWP)
Real NAV backtest
A ₹10,00,000 corpus withdrawing ₹5,000/month since Jul 2016 would still hold ₹23,30,254.
Fund vs Benchmark (TRI)
Same SIP, benchmark total-return index
The same SIP would be worth ₹12,97,469 in this fund vs ₹16,29,966 in the benchmark — underperformance of ₹3,32,497.
Buying the worst day
Real NAV backtest
₹1,00,000 invested on the worst market day of the last 10 years (Jul 2016 – Jul 2026) (22 Mar 2020) would be ₹4,39,803 today (4.40×).
Historical simulation using actual published NAVs for the stated period. Past performance may or may not be sustained in the future. Not investment advice.
Risk Metrics
Trailing 1 year, annualised-0.04
Sharpe Ratio
-0.01
Alpha
0.11
Beta
-0.03
Sortino
16.31%
Std Dev
-14.10%
Max Drawdown
Performance Comparison
Sectoral allocation
as of 31 May 2026- Pharmaceuticals & Biotechnology9.63%
- Banks8.91%
- Auto Components8.11%
- Industrial Products7.97%
- Consumer Durables7.45%
- Finance5.65%
- Capital Markets5.51%
- IT - Software5.40%
- Electrical Equipment4.62%
- Retailing3.51%
- Chemicals & Petrochemicals3.34%
- Insurance3.10%
Each sector links to the mutual funds most exposed to it.
Thinking about UTI Mid Cap Fund · Regular · Growth?
Talk to our AMFI-registered team — free, no pressure. We'll help you see if this fund fits your goals.
Fund Details
Available transactions
Portfolio holdings
portfolio shared with UTI Mid Cap Fund - Regular Plan - IDCW
- 1Polycab India Ltd2.40%
- 2Pb Fintech Ltd2.37%
- 3Tube Investments Of India Ltd2.33%
- 4Max Financial Services Ltd.2.19%
- 5Suzlon Energy Ltd.2.11%
- 6Coforge Ltd2.04%
- 7Bse Ltd2.01%
- 8Phoenix Mills Ltd1.94%
- 9Federal Bank Ltd.1.87%
- 10Ajanta Pharma Ltd.1.85%
Investment Objective
UTI Mid Cap Fund · Regular · Growth seeks to generate long-term capital appreciation by investing in mid-cap companies — ranked 101st to 250th by market capitalisation. These companies offer a balance of growth potential and relative stability, making them suitable for investors with moderate to high risk appetite.
About This Fund
UTI Mid Cap Fund · Regular · Growth is a Mid Cap mutual fund offered by UTI Mutual Fund. The fund has been operational for over 22 years. It manages assets worth ₹11,473 Cr, reflecting investor confidence in the fund's strategy. It benchmarks its performance against NIFTY Midcap 150 TRI. The current expense ratio is 1.77%.
Who Should Invest?
- •Aggressive investors comfortable with significant short-term volatility
- •Investors with a long-term horizon of 7+ years who can ride out market cycles
- •SIP investors who can benefit from rupee cost averaging during market fluctuations